C12 boost RT for adenoid cystic carcinomas (ACC)


The details of the COSMIC trial have been published [5]. Goal of the trial was to evaluate toxicity in dose-escalated treatment with intensity-modulated radiotherapy (IMRT) and carbon ion boost for malignant salivary gland tumors (MSGT) of the head and neck. It was a prospective phase II trial. The dose to the primary target volume (boost volume) was increased to 8 x 3 GyE carbon ions compared to 6 x 3 GyE carbon ions at the GSI. The extended target volume of possible microscopic spread was treated using 25 x 2 Gy of photons in an IMRT technique. Primary endpoint was mucositis CTC°III, secondary endpoints were local control, progression-free survival, and toxicity. A total of 50 patients were included in this trial and recruitment was finished in April 2011. An interim analysis was published in May 2012 [6]. Long term results from patients with adenoid cystic carcinoma treated with additional carbon ion boost revealed significantly higher local tumor control and also significantly higher overall survival[21].